iQ Group Global member Antisoma Therapeutics has secured a worldwide licence for Harvard University’s eRapid technology for creating at-home diagnostic testing.

The new diagnostic technology, developed at the Wyss Institute for Biologically Inspired Engineering at Harvard University, was designed with exclusivity in cancer, respiratory viral illnesses and immune/allergic disease.

The affinity-based electrochemical sensing platform will be used to create rapid point-of-care diagnostic tests to detect a range of biomarkers, including prostate-specific antigen (PSA), Covid-19 antibodies and histamine.

It can be used for the simultaneous detection of a wide range of biomarkers, with high selectivity and sensitivity in complex biological fluids.

At present, the eRapid technology can be utilised for the detection of glucagon, insulin, IL6, and COVID IgM and/or IgG antibodies. This can indicate an individual’s SARS-CoV-2 virus immunity.

The iQ Group Global CEO and chairman Dr George Syrmalis said: “Our priority is to continue developing and commercialising the saliva quantitative Covid test, standardised against the World Health Organization (WHO) reference standard, which will allow patients and physicians to determine immunity based on antibody load and that will then determine if additional Covid vaccination booster shots are needed.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData

“This level of accuracy will rationalise repeat vaccination protocols, increase the efficiency of health care services while dramatically reducing costs to governments and the health care sector.

“The eRapid diagnostic tests have been shown to successfully detect IL6, insulin and glucagon, among other clinically relevant target molecules ranging in size from 100Da to 150,000Da. The sensors can also be reused multiple times.”

The company has been partnered with the Wyss Institute for the development of rapid point-of-care SARS-CoV-2 antibody tests since 2020.

In the same year, The iQ Group Global initially secured access to the eRapid technology for a limited-term, on a non-exclusive basis.